Emerging Companies on the Rise
Fortune India’s The Next 500 event showed how emerging companies are scaling new levels.
dr lal pathlabs
August 2023
December 2022
May 2022
January 2021
May 2019
March 2019
October 2018
Diagnostics stocks surge on Covid scare; Dr. Lal PathLabs, Vijaya Diagnostic rise up to 8%
Among diagnostics companies, Vijaya Diagnostic Centre topped the gainers’ chart, followed by Dr. Lal PathLabs, Metropolis Healthcare, and Thyrocare Technologies.
Dr. Lal Pathlabs shares hit 52-week low post Q4 results; here’s why
Dr. Lal Pathlabs has reported a 27% YoY fall in consolidated net profit to ₹62 crore in Q4FY22 due to a decline in revenue from Covid and allied business.
Building the Metropolis of the future
Ameera Shah's Metropolis Healthcare is all set to acquire Hitech Diagnostics Centre. Here's Fortune India's earlier story on how Shah is transforming her fast-growing pathlab company.
‘Going public will help build credibility with stakeholders’
By holding itself accountable to committed results and highest governance standards, Metropolis hopes to attract and retain the support of marquee investors for future growth.
TA Associates: Nine years and counting
Global PE major TA Associates, which completed nine years in India, is focussed on making more investments here, particularly in the areas of technology, and consumer and financial services.
Dr Lal PathLabs: The alchemy of growth
From 10 clinical labs in 2005, Dr Lal PathLabs has become the largest diagnostic chain in north India and is looking to expand to the eastern and southern markets. Can it sustain its momentum?
